Ensysce Biosciences Complies Again with Nasdaq

San Diego, CA – Ensysce Biosciences Inc. (NASDAQ: ENSC), a pharmaceutical company focused on developing advanced pain management solutions that mitigate the risk of opioid abuse and overdose, has announced that as of May 24, 2024, it remains in compliance with the equity requirements stipulated by Nasdaq’s Listing Rule 5550(b)(1). This follows the Hearing Panel's decision on February 26, 2024, ensuring that Ensysce's common stock will continue to be traded on the Nasdaq Capital Market.

Innovative Approaches to Pain Management

Ensysce Biosciences stands out in the pharmaceutical industry with its proprietary technology platforms designed to create safer prescription medications. Their Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) technologies are pivotal in producing tamper-resistant pain relief medications. These innovations are critical in addressing the dual crises of opioid abuse and overdose, providing safer alternatives for patients experiencing severe pain.

TAAP and MPAR Technologies

The TAAP™ platform focuses on preventing prescription drug abuse by activating medication only in the presence of specific enzymes like trypsin, reducing the potential for abuse. The MPAR® technology is designed to prevent abuse and accidental overdose by limiting the effective dosage even if multiple pills are ingested simultaneously. These technologies are protected by a broad intellectual property portfolio, ensuring a wide array of tamper-resistant drug compositions.

Future Outlook

Ensysce is committed to advancing its clinical programs and addressing the opioid crisis through innovative and safer drug solutions. The company continues to focus on developing and commercializing its unique TAAP™ and MPAR® platforms to provide pain relief options that reduce the risk of abuse and overdose.

Conclusion

Ensysce Biosciences Inc. remains a pivotal player in the movement towards safer opioid medication alternatives. By securing its compliance with Nasdaq listing requirements, the company reinforces its commitment to innovation in pain management and its ongoing efforts to combat the opioid crisis with advanced pharmaceutical technologies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!